These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

437 related items for PubMed ID: 21326082

  • 41. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial.
    Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, Balis DA, Canovatchel W, Meininger G.
    Lancet; 2013 Sep 14; 382(9896):941-50. PubMed ID: 23850055
    [Abstract] [Full Text] [Related]

  • 42. UKPDS 28: a randomized trial of efficacy of early addition of metformin in sulfonylurea-treated type 2 diabetes. U.K. Prospective Diabetes Study Group.
    Diabetes Care; 1998 Jan 14; 21(1):87-92. PubMed ID: 9538975
    [Abstract] [Full Text] [Related]

  • 43. Long-term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104-week VERTIS MET trial.
    Gallo S, Charbonnel B, Goldman A, Shi H, Huyck S, Darekar A, Lauring B, Terra SG.
    Diabetes Obes Metab; 2019 Apr 14; 21(4):1027-1036. PubMed ID: 30614616
    [Abstract] [Full Text] [Related]

  • 44. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G, Gaddi AV, Piccinni MN, Ciccarelli L, Salvadeo S, Peros E, Ghelfi M, Ferrari I, Cicero AF.
    Pharmacotherapy; 2005 May 14; 25(5):637-45. PubMed ID: 15899724
    [Abstract] [Full Text] [Related]

  • 45. Efficacy and safety of hydroxychloroquine in the treatment of type 2 diabetes mellitus: a double blind, randomized comparison with pioglitazone.
    Pareek A, Chandurkar N, Thomas N, Viswanathan V, Deshpande A, Gupta OP, Shah A, Kakrani A, Bhandari S, Thulasidharan NK, Saboo B, Devaramani S, Vijaykumar NB, Sharma S, Agrawal N, Mahesh M, Kothari K.
    Curr Med Res Opin; 2014 Jul 14; 30(7):1257-66. PubMed ID: 24669876
    [Abstract] [Full Text] [Related]

  • 46. Efficacy and Safety of Pioglitazone versus Glimepiride after Metformin and Alogliptin Combination Therapy: A Randomized, Open-Label, Multicenter, Parallel-Controlled Study.
    Kim JM, Kim SS, Kim JH, Kim MK, Kim TN, Lee SH, Lee CW, Park JY, Kim ES, Lee KJ, Choi YS, Kim DK, Kim IJ.
    Diabetes Metab J; 2020 Feb 14; 44(1):67-77. PubMed ID: 31339011
    [Abstract] [Full Text] [Related]

  • 47. Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea.
    Goldstein BJ, Pans M, Rubin CJ.
    Clin Ther; 2003 Mar 14; 25(3):890-903. PubMed ID: 12852706
    [Abstract] [Full Text] [Related]

  • 48. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
    Ridderstråle M, Svaerd R, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial investigators.
    Cardiovasc Diabetol; 2013 Sep 05; 12():129. PubMed ID: 24007456
    [Abstract] [Full Text] [Related]

  • 49. The efficacy and safety of adding either vildagliptin or glimepiride to ongoing metformin therapy in patients with type 2 diabetes mellitus.
    Kim G, Oh S, Jin SM, Hur KY, Kim JH, Lee MK.
    Expert Opin Pharmacother; 2017 Aug 05; 18(12):1179-1186. PubMed ID: 28714741
    [Abstract] [Full Text] [Related]

  • 50. Effect of bromocriptine-QR on glycemic control in subjects with uncontrolled hyperglycemia on one or two oral anti-diabetes agents.
    Vinik AI, Cincotta AH, Scranton RE, Bohannon N, Ezrokhi M, Gaziano JM.
    Endocr Pract; 2012 Aug 05; 18(6):931-43. PubMed ID: 23186965
    [Abstract] [Full Text] [Related]

  • 51. Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).
    Bell DS, Dharmalingam M, Kumar S, Sawakhande RB.
    Diabetes Obes Metab; 2011 Sep 05; 13(9):800-5. PubMed ID: 21477065
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
    Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, EMPA-REG H2H-SU trial investigators.
    Lancet Diabetes Endocrinol; 2014 Sep 05; 2(9):691-700. PubMed ID: 24948511
    [Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 22.